A comprehensive 16 loci-based DNA fingerprinting dataset of a broad tumor cell line panel for cancer research

Alessio Somaschini(Nerviano Medical Sciences), Roberta Bosotti(Human Technopole), Emanuela Scacheri(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences), Angelo Nuzzo(Nerviano Medical Sciences), Dario Ballinari(Nerviano Medical Sciences), Giorgio Ukmar(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia)
EMBnet journal
April 29, 2012
10.14806/ej.18.a.419
Cited by 0

Related Papers

Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
|Molecular Oncology|2014|156
Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
|Journal of Medicinal Chemistry|2009|128